C-X-C receptor 4 (CXCR4)-directed imaging and therapy in NEN patients with varying tumor aggressiveness – Diagnostic performance and eligibility for CXCR4-targeted theragnostics

#3610

Introduction: C-X-C motif chemokine receptor 4 (CXCR4) has emerged as a promising target in neuroendocrine neoplasms (NEN).

Aim(s): To test the diagnostic performance of CXCR4-PET/CT in NEN relative to guideline-compatible imaging (GCI) and to determine patients eligible for treatment using a ß-emitting theragnostic equivalent.

Materials and methods: We included 25 patients with a broad range of tumor aggressiveness (G1 NEN, 3/25 [12%]; G2 NEN, 7/25 [28%]; G3 NEN, 2/25 [8%]; neuroendocrine carcinoma (NEC), 11/25 [44%]; mixed neuroendocrine non-neuroendocrine neoplasms (MiNEN), 2/25 [8%]). All subjects received GCI as endorsed by current ENETS guidelines, including 68Ga-DOTATOC (low-grade [G1, G2]) and 18F-FDG (high-grade [G3, MiNEN, NEC]). Patients also underwent CXCR4-directed PET/CT using 68Ga-PentixaFor, without treatment between scans. We tested the diagnostic performance and eligibility for CXCR4-directed radioligand therapy (RLT).

Conference:

Presenting Author: Weich A

Authors: Weich A, Schlötelburg W, Hartrampf P, Serfling S, Heinrich M,

Keywords: CXCR4, radioligand therapy, PET, theragnostics, imaging,